Sermorelin Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Sermorelin dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Sermorelin.
Dosing Protocols
Standard Adult Protocol (first-time users):
- Dose: 200-300 mcg subcutaneous injection
- Timing: Once nightly at bedtime (within 1 hour of sleep onset)
- Site: Rotate between abdomen, thigh, and flank subcutaneous tissue
- Duration: 12-16 weeks minimum to assess response
Reconstitution: Reconstitute the lyophilized vial with bacteriostatic water at a concentration of 1 mg/mL. A 300 mcg dose is 0.3 mL (30 units on a U-100 insulin syringe).
Why bedtime: Sermorelin aligns with the natural nocturnal GH pulse that peaks roughly 60-90 minutes after sleep onset. Injecting in the hours before bed amplifies this pulse rather than creating a competing one. Daytime injection is pharmacologically less effective because somatostatin tone is higher during waking hours.
Food timing: Sermorelin should ideally be taken in a fasted state (3+ hours after the last meal), because elevated insulin and blood glucose blunt GH release through somatostatin potentiation. Bedtime dosing naturally aligns with the end of the daily eating window.
Tracking response: Consider baseline labs before starting — IGF-1, fasting insulin, HbA1c, and basic metabolic panel. Recheck IGF-1 at weeks 6 and 12 to confirm response and titrate dose if needed. Target is the upper-normal range for age, not supraphysiologic values.
Optimized Adult Protocol (responders after 3 months):
- Dose: 300-500 mcg subcutaneous nightly
- Timing: Bedtime, fasted
- Cycle: Continuous use, 5 days on / 2 days off weekly to prevent receptor desensitization (optional but commonly used)
- Monitoring: IGF-1 every 3 months, fasting glucose every 6 months
Strategic considerations at this tier:
Some practitioners transition users from sermorelin alone to a GHRH + GHS combination at the intermediate stage — typically sermorelin 200-300 mcg paired with ipamorelin 200-300 mcg in the same injection. This exploits the GHRH × ghrelin synergy (3-5x amplification of GH pulse amplitude) while keeping the pulsatile pharmacology sermorelin provides.
Weekend-off cycling is used by some protocols to protect against receptor adaptation, though the short half-life of sermorelin makes desensitization less of a concern than with CJC-1295-DAC or MK-677. Continuous daily dosing for 4-6 months followed by a 4-week washout is another common approach.
Performance and Recomposition Stack (informed users only):
- Sermorelin: 400-500 mcg SC nightly
- Ipamorelin: 200-300 mcg SC nightly (same injection)
- Optional addition: BPC-157 250-500 mcg SC BID for connective tissue support during training intensification
Cycling strategy:
- 16 weeks on / 4 weeks off
- Quarterly IGF-1 and comprehensive metabolic monitoring
- Consider adding fasting insulin and HbA1c tracking if combining with aggressive training and caloric surplus
Combinations to understand:
- With BPC-157 + TB-500: Aggressive injury recovery and connective tissue remodeling stack
- With semaglutide or tirzepatide: Counter-intuitive but can work — sermorelin's anabolic signal helps preserve lean mass during GLP-1-driven fat loss (see Sigalos 2018 for theoretical framework). Requires careful calorie and protein management.
- With testosterone replacement: Well-established synergy in men with clinically low testosterone. The anabolic effects are additive.
Combinations to avoid or manage:
- With tesamorelin: Redundant mechanism. Choose one GHRH analog at a time.
- With CJC-1295-DAC: Mechanistically redundant. The DAC-modified version has an 8-day half-life, which eliminates the pulsatile pharmacology that is sermorelin's main advantage.
- With exogenous HGH: Pointless. If you're on rhGH, sermorelin adds nothing because negative feedback from elevated IGF-1 will suppress endogenous pituitary output regardless.
When to discontinue:
Stop sermorelin if you develop persistent joint pain, peripheral edema, carpal tunnel symptoms, elevated fasting glucose, or any hypersensitivity reaction. These signs suggest IGF-1 elevation beyond the optimization range.
Commonly Stacked With
Synergistic Combinations
Sermorelin + Ipamorelin (the classic GHRH + GHS pair): This is the most well-established combination in the peptide space. Sermorelin drives GHRH receptor activation; ipamorelin drives GHS-R1a activation on the same somatotrophs. The two pathways converge intracellularly and produce a 3-5x amplification of GH pulse amplitude compared to either compound alone (Bowers et al., 1991). Ipamorelin's selectivity (no ACTH, cortisol, or prolactin elevation) makes this a clean pairing.
Sermorelin + BPC-157: Complementary rather than synergistic at the GH axis level — BPC-157 supports connective tissue, GI mucosal integrity, and soft-tissue healing, while sermorelin supports systemic anabolism. Popular in injury recovery and training intensification contexts.
Sermorelin + Testosterone replacement (in hypogonadal men): Well-established clinical synergy. Testosterone drives muscle protein synthesis directly; sermorelin amplifies GH/IGF-1-mediated anabolic signaling. The combination can substantially improve body composition outcomes in men with genuine hormonal deficiency.
Situational or Redundant
Sermorelin + CJC-1295 (no-DAC): Both are GHRH analogs. Sermorelin's half-life is 10-20 min; CJC-1295 (no-DAC) is slightly longer. Overlapping mechanism with minimal advantage. Pick one.
Sermorelin + Tesamorelin: Redundant. Both target GHRHR. If visceral adiposity is the primary goal, tesamorelin has the specific FDA-approved indication and trial data. If broader GH optimization is the goal, sermorelin is less expensive and more flexibly dosed.
Avoid or Reconsider
Sermorelin + CJC-1295-DAC: Mechanistic conflict. The DAC version has an 8-day half-life and produces continuous rather than pulsatile GHRH receptor stimulation. Adding pulsatile sermorelin on top of continuous CJC-DAC eliminates sermorelin's pulsatility advantage and adds no meaningful GH release above what CJC-DAC is already producing. Choose one or the other.
Sermorelin + MK-677 (ibutamoren): Not contraindicated but redundant for GH-axis purposes. MK-677 provides sustained 24-hour GHS-R1a activation. Adding a short-acting GHRH pulse on top of continuous ghrelin-mimetic signal produces diminishing returns. Consider pairing MK-677 with a long-acting GHRH (CJC-1295-DAC) instead, or sermorelin with a short-acting GHS (ipamorelin).
Sermorelin + Exogenous HGH: Pharmacologically counterproductive. Exogenous recombinant GH suppresses endogenous GHRH and somatotroph activity via IGF-1 negative feedback. Sermorelin becomes functionally inert in this context.
Related Compound Pages
- CJC-1295 — Long-acting GHRH analog for comparison
- Ipamorelin — Selective GHS-R1a pentapeptide; the standard synergistic partner
- Tesamorelin — FDA-approved GHRH analog for HIV lipodystrophy and VAT reduction
- MK-677 — Oral GHS-R1a agonist for comparison
- BPC-157 — Connective tissue recovery stack partner
- TB-500 — Thymosin-beta-4 fragment for soft-tissue healing
- NAD+ — Mitochondrial cofactor often stacked for anti-aging
- Epithalon — Pineal peptide for circadian and telomere support
- GHK-Cu — Copper peptide for skin and tissue remodeling
Side Effects & Safety
Contraindications
Sermorelin is contraindicated or requires extreme caution in: - **Active malignancy** — particularly any hormone-responsive cancer (breast, prostate, endometrial) given the theoretical concern that elevated IGF-1 could promote tumor growth - **Strong family history of GH-axis responsive cancers** — use only under specialist supervision with close monitoring - **Pregnancy and lactation** — no established safety data; avoid - **Known hypersensitivity** to sermorelin, GHRH analogs, or any excipient - **Severe untreated sleep apnea** — theoretical concern about upper airway soft tissue growth; stabilize with CPAP/APAP before initiating - **Acute critical illness** — GH-axis stimulation is inappropriate during sepsis, post-surgical recovery, multiple trauma, or respiratory failure states - **Diabetic ketoacidosis or severe uncontrolled diabetes** — resolve the metabolic state first - **Active proliferative retinopathy** — relative contraindication; discuss with ophthalmologist **Relative cautions requiring monitoring:** - Borderline fasting glucose or HbA1c — monitor closely; discontinue if deterioration - History of benign adenomas (pituitary, adrenal, thyroid) — imaging surveillance recommended - Strong family history of colon polyps — baseline colonoscopy before starting, surveillance per gastroenterology guidance - Concurrent glucocorticoid therapy — pharmacodynamic interference; GH-axis stimulation is less effective in pharmacologic steroid contexts **Age-related note:** Sermorelin has been used in pediatric GHD populations historically with FDA approval, but use in healthy older adults for anti-aging purposes remains off-label and should only be undertaken with informed consent about the limitations of available long-term safety data.
Additional Notes
Standard Dosing Reference
| User Tier | Nightly Dose | Frequency | Typical Use |
|---|---|---|---|
| Beginner | 200-300 mcg | 7 nights/week | First 12-16 weeks |
| Intermediate | 300-500 mcg | 5-7 nights/week | Months 4-12 |
| Advanced | 400-500 mcg | 5-7 nights/week (stacked) | Continuous with cycling |
Timing Rules (important)
- Inject at bedtime — within 1 hour of sleep onset to synchronize with the natural nocturnal GH pulse.
- Fasted state — at least 3 hours after your last meal. Elevated blood glucose and insulin blunt GH release through increased somatostatin tone.
- No alcohol within 2 hours — alcohol suppresses GH secretion.
- Consistent timing — the GH axis entrains to regular dosing schedules, so variable timing reduces effectiveness.
Concentration and Volume
A standard reconstitution yields 1 mg/mL:
- 200 mcg dose = 0.2 mL = 20 units on a U-100 insulin syringe
- 300 mcg dose = 0.3 mL = 30 units
- 500 mcg dose = 0.5 mL = 50 units
A 2 mg vial reconstituted with 2 mL of bacteriostatic water will last approximately 10 days at 200 mcg/day or 4-5 days at 500 mcg/day.
Monitoring
- Baseline: IGF-1, fasting insulin, HbA1c, comprehensive metabolic panel, IGFBP-3 (optional)
- Week 6: Recheck IGF-1 to confirm response
- Week 12: IGF-1 + fasting glucose; titrate dose based on trajectory
- Every 3 months thereafter: IGF-1 alone; every 6 months the full panel
Target IGF-1: Upper quartile of the age-adjusted reference range. Not the upper limit, and not supraphysiologic. If IGF-1 climbs above the reference range, reduce the dose or take a washout period.
When to Not Dose
- If you are in a caloric deficit severe enough to cause low energy availability, sermorelin's anabolic signal will be blunted and the dose is largely wasted
- If you have active infection with fever — postpone until resolved
- If fasting blood glucose is consistently above 110 mg/dL, address the metabolic state before adding GH-axis stimulation
Where to Buy Sermorelin
Compare 8 listings across 4 vendors — from $24.99
Frequently Asked Questions
What is the recommended Sermorelin dosage?
Dosage for Sermorelin varies by protocol. Consult a qualified healthcare provider.
How often should I take Sermorelin?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Sermorelin need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Sermorelin side effects?
## Common Effects - **Injection site reactions** — The most frequently reported issue. Mild erythema, transient itching, or a small wheal at the subcutaneous injection site. Usually self-resolves within 30-60 minutes and rarely requires intervention beyond site rotation. - **Facial flushing** — A warm, pink flush of the face and neck minutes after injection, caused by GHRH-induced vasodilation. Typically fades within 10-20 minutes and diminishes as the body adapts over 2-4 weeks. - **Mild headache** — Infrequent, usually resolves with hydration. More common in the first week of therapy. - **Vivid dreams** — Not always an adverse effect; many users report enhanced dream recall in association with the improved slow-wave sleep that sermorelin promotes. ## Less Common Effects - **Transient hunger** — GHRH has modest central appetite-stimulating activity, though this is significantly less pronounced than with ghrelin-mimetics like ipamorelin or MK-677. - **Mild fluid retention** — Typically minor and self-limiting. More pronounced in users with higher initial doses or those combining sermorelin with ghrelin mimetics. - **Insulin sensitivity changes** — GH-axis stimulation can induce modest reductions in insulin sensitivity over time. Users with pre-existing insulin resistance or borderline fasting glucose should monitor HbA1c and fasting insulin periodically. - **Dysgeusia** — Rare reports of a metallic taste immediately after injection. ## Rare but Notable - **Hypersensitivity reactions** — Localized swelling beyond the injection site or systemic allergic response. Immediate discontinuation warranted. - **Elevated transaminases** — Rare; reversible on discontinuation. ## Theoretical Long-Term Concerns Like all GH-axis interventions, sermorelin carries a **theoretical concern around chronically elevated IGF-1 and cancer risk**. No causal link has been demonstrated in clinical trials to date, but the mechanistic plausibility — IGF-1 is a pro-mitogenic signal — argues for conservative dosing, periodic IGF-1 monitoring, and avoidance in individuals with personal or strong family history of hormonally-sensitive cancers. Because sermorelin preserves pulsatility and cannot elevate IGF-1 above the somatostatin ceiling, this risk is generally considered lower than with continuous recombinant GH administration, but it is not zero. ## Contraindications to Note - Active malignancy (particularly GH-sensitive tumors) - Pregnancy and lactation (no established safety data) - Severe respiratory impairment or sleep apnea (theoretical concern for upper airway tissue growth) - Known hypersensitivity to sermorelin or any excipient
Where can I buy Sermorelin?
Compare 8 listings from 4 vendors on our price comparison page — starting from $24.99.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.